JOURNAL OF SOCIAL SCIENCES, HUMANITIES AND INNOVATION

Vol 2 Issue 1 (2026)

http://jsshi.org/

Gut Microbiome-Brain-Liver Crosstalk in Metabolic Dysfunction: Mechanisms and Therapeutic Opportunities

Junseo Lim, Alvin Charlie, Seungmin Seok, Axel Craig

[1, 2,3,4]Faculty of Science, University of Melbourne, Melbourne, Australia

Keywords:

Gut Microbiome, Metabolic Dysfunction, Inter-organ Crosstalk, Vagus Nerve Signaling, Therapeutic Interventions.

Abstract:

The human body operates as a highly integrated network of organ systems, wherein the gut, brain, and liver form a critical tripartite axis responsible for maintaining metabolic homeostasis. Disruption in any single component of this system frequently cascades into systemic metabolic dysfunction, precipitating conditions such as obesity, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. This paper provides a comprehensive academic analysis of the gut microbiome-brain-liver crosstalk, elucidating the complex biochemical, neural, and immunological mechanisms that underpin inter-organ communication. By exploring the production and systemic circulation of microbe-derived metabolites, including short-chain fatty acids, secondary bile acids, and lipopolysaccharides, we delineate how the intestinal bioreactor influences both hepatic lipid metabolism and central neuroendocrine regulation. Furthermore, we examine the critical role of the vagus nerve and the enteric nervous system in facilitating rapid bidirectional signaling between the intestinal lumen and the central nervous system. Advanced analytical methodologies, such as multi-omics integration and germ-free animal models, are discussed in the context of mapping these complex communication networks. Finally, we explore emerging therapeutic opportunities that target this tripartite axis, evaluating the clinical potential of microbial interventions, targeted pharmacotherapies, and precision nutrition. Ultimately, this analysis underscores the necessity of a paradigm shift from organ-centric treatments toward holistic, network-based interventions in the management of systemic metabolic diseases.

1. INTRODUCTION

1.1 The Tripartite Axis in Human Physiology

For decades, the standard biomedical approach to metabolic diseases was primarily organ-centric, isolating pathophysiological phenomena to the specific tissues where symptoms most prominently manifested. The liver was studied as the primary locus of lipid and glucose dysregulation, the brain was viewed as the isolated command center for appetite and energy expenditure, and the gastrointestinal tract was considered merely an absorptive conduit for nutrients. However, recent advances in systems biology have forced a profound paradigm shift [1]. It is now unequivocally understood that metabolic homeostasis relies upon a highly sophisticated, continuous, and bidirectional flow of information among the gut microbiome, the brain, and the liver. This integrated network, often referred to as the gut-brain-liver axis, functions as a master regulatory circuit. The gut microbiota, a densely populated ecological community of trillions of microorganisms, acts as an environmental sensor and a massive biochemical factory. The liver serves as the primary metabolic clearinghouse, processing microbial signals alongside dietary substrates. Concurrently, the central nervous system, particularly hypothalamic and brainstem circuits, integrates neural and humoral signals to coordinate feeding behavior, energy expenditure, and peripheral tissue metabolism [2].

The communication channels linking these three domains are multifaceted, comprising neural pathways, such as the afferent and efferent branches of the vagus nerve, as well as endocrine and immunological circulatory routes. When an individual consumes food, the resident microbes ferment complex dietary polysaccharides, yielding a vast array of bioactive molecules that immediately begin interfacing with local intestinal enteroendocrine cells and immune sensors [3]. These local interactions trigger the release of gut peptides that communicate satiation to the brain while simultaneously preparing the liver for incoming nutrients. Furthermore, metabolites cross the epithelial barrier, entering the portal vein to interact directly with hepatic receptors, or bypassing hepatic clearance to cross the blood-brain barrier. The sheer complexity of this tripartite axis suggests that human metabolism is intrinsically a co-metabolism, representing an evolutionary symbiosis between mammalian host genetics and the vast genetic repertoire of the microbiome [4].

1.2 Rising Prevalence of Metabolic Dysfunction

The necessity of understanding this axis is underscored by the unprecedented global rise in metabolic dysfunction. Conditions spanning the metabolic syndrome spectrum, including visceral obesity, insulin resistance, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease, have reached epidemic proportions. Traditional interventions relying solely on caloric restriction or single-target pharmacological agents frequently fail to achieve long-term remission, often because they do not address the underlying systemic miscommunication driving the pathology. In a state of chronic metabolic dysfunction, the delicate balance of the gut-brain-liver axis is severely perturbed. Dietary patterns high in refined carbohydrates and saturated fats induce profound shifts in microbial ecology, a state termed dysbiosis. This dysbiosis not only alters the profile of secreted metabolites but also compromises the integrity of the intestinal mucosal barrier, initiating a cascade of low-grade systemic

inflammation that profoundly impacts both hepatic function and neuroinflammation. Recognizing the interconnected nature of these events is critical for developing next-generation therapeutic modalities that can simultaneously recalibrate the entire metabolic network rather than merely suppressing downstream symptoms.

2. Literature Review and Biological Background

2.1 The Gut Microbiome as a Central Hub

The human gastrointestinal tract harbors an immensely diverse consortium of bacteria, archaea, fungi, and viruses, with bacteria being the most extensively characterized mediators of host metabolism. The compositional balance of this microbial community is highly responsive to environmental inputs, particularly diet, and plays a foundational role in determining systemic metabolic health. In healthy individuals, the microbiome is typically characterized by high taxonomic diversity and a functional capacity optimized for the extraction of energy from indigestible dietary fibers. The fermentation of these fibers produces short-chain fatty acids, predominantly acetate, propionate, and butyrate, which serve as foundational signaling molecules in the gut-brain-liver axis. Butyrate is widely recognized for its localized role in providing energy to colonocytes and maintaining the integrity of tight junction proteins between epithelial cells. However, a significant proportion of acetate and propionate enters the portal circulation, acting directly on the liver to influence gluconeogenesis and lipogenesis [5]. Moreover, a fraction of these short-chain fatty acids reaches systemic circulation, where they have been shown to cross the blood-brain barrier and influence the function of microglia, thereby modulating central neuroinflammation and satiety pathways [6].

Beyond short-chain fatty acids, the microbiome is intricately involved in the metabolism of primary bile acids, which are synthesized from cholesterol in the liver and secreted into the duodenum to facilitate dietary lipid absorption. Upon reaching the distal small intestine and colon, these primary bile acids are enzymatically modified by gut bacteria through deconjugation and dehydroxylation processes to form secondary bile acids. This biotransformation is not merely a waste management process; secondary bile acids are potent signaling molecules that activate specific nuclear and membrane-bound receptors, notably the farnesoid X receptor and the G-protein-coupled bile acid receptor TGR5, distributed throughout the intestinal epithelium [7]. The activation of these receptors stimulates the release of incretin hormones like glucagon-like peptide-1 and fibroblast growth factor 19, which enter the circulation to exert profound regulatory effects on hepatic bile acid synthesis, glucose metabolism, and central appetite regulation [8].

2.2 The Gut-Liver Axis Mechanisms

The anatomical connection between the gut and the liver is direct and robust, facilitated primarily by the portal vein, which delivers approximately seventy percent of the liver blood supply. This direct conduit means that the liver represents the first pass for virtually all substances absorbed from the gastrointestinal tract, placing it at the front line of defense against

microbial products and toxins. In a state of health, a robust intestinal barrier prevents the translocation of intact microbes and large immunostimulatory molecules. However, the Western diet, characterized by low fiber and high processed fats, frequently induces microbial dysbiosis that degrades the protective mucus layer and downregulates tight junction protein expression. This increased intestinal permeability allows for the paracellular leakage of microbial-associated molecular patterns, such as lipopolysaccharides derived from the outer membrane of Gram-negative bacteria, into the portal circulation.

Upon reaching the liver, these lipopolysaccharides bind to Toll-like receptor 4 expressed on the surface of Kupffer cells, the resident hepatic macrophages. The activation of Toll-like receptor 4 triggers an intracellular signaling cascade culminating in the translocation of nuclear factor kappa B to the nucleus, promoting the transcription and release of pro-inflammatory cytokines such as tumor necrosis factor alpha and interleukin 6 [11]. This sustained hepatic inflammation impairs insulin signaling cascades within hepatocytes, leading to unsuppressed hepatic glucose production and exacerbating systemic insulin resistance. Furthermore, the inflammatory milieu activates hepatic stellate cells, transitioning them into myofibroblast-like cells that deposit extracellular matrix proteins, ultimately driving the progression from simple hepatic steatosis to severe steatohepatitis and fibrosis. The continuous bombardment of the liver by dysbiotic gut-derived factors thus serves as a primary engine for the progression of metabolic liver disease.

2.3 The Gut-Brain Axis and Neurometabolic Control

While the liver processes the biochemical output of the gut, the central nervous system continuously monitors and regulates this entire system through the gut-brain axis. This communication relies heavily on the vagus nerve, a major neural highway connecting the enteric nervous system to the brainstem. Vagaries of sensory afferent fibers densely innervate the mucosal layers of the gastrointestinal tract. Although these nerve endings do not typically cross the epithelial barrier, they are positioned in close proximity to enteroendocrine cells, functioning as highly sensitive biological transducers. When gut microbes metabolize nutrients, the resulting chemical signals prompt enteroendocrine cells to release neurotransmitters and peptide hormones, such as serotonin, cholecystokinin, and peptide YY. These molecules bind to receptors on adjacent vagal afferent terminals, generating action potentials that rapidly travel up the nodose ganglion to the nucleus of the solitary tract in the brainstem [9].

From the brainstem, this metabolic information is relayed to higher-order integration centers, particularly the arcuate nucleus of the hypothalamus. The hypothalamus interprets these signals to adjust feeding behavior, modulating the balance between orexigenic and anorexigenic neuropeptide expression. For instance, robust vagal signaling indicative of a nutrient-rich, microbially active gut environment promotes satiety and increases energy expenditure. Conversely, in the context of diet-induced dysbiosis, aberrant signaling can blunt these satiety pathways, leading to hyperphagia and weight gain [10]. Additionally, systemic inflammation originating from a leaky gut can directly impact the brain. Circulating cytokines and translocated microbial products can alter the permeability of the blood-brain barrier. Microglia, the resident

immune cells of the central nervous system, respond to these systemic inflammatory signals by shifting toward an activated, pro-inflammatory phenotype. This neuroinflammation disrupts hypothalamic insulin and leptin signaling, further entrenching metabolic dysfunction by causing central resistance to key metabolic hormones [12].

3. Analytical Methodology of Axis Crosstalk

3.1 Multi-Omics Approaches to Microbiome Profiling

The investigation of the gut microbiome-brain-liver axis requires sophisticated analytical methodologies capable of capturing the immense complexity of these biological networks. Historically, microbiological research relied on culture-based techniques, which were inherently limited by the inability to culture the vast majority of anaerobic intestinal taxa in vitro. The advent of high-throughput next-generation sequencing revolutionized the field, enabling the comprehensive characterization of microbial communities through culture-independent means. The most ubiquitous method involves the targeted amplification and sequencing of the 16S ribosomal RNA gene, which contains hypervariable regions that serve as phylogenetic markers to identify bacterial taxa. While 16S sequencing provides cost-effective taxonomic profiling, it offers limited resolution regarding the actual functional capabilities of the microbiome. To overcome this, researchers increasingly employ shotgun metagenomic sequencing, which involves the random shearing and sequencing of all genomic DNA present in a biological sample. This approach not only provides species- and strain-level taxonomic resolution but also allows for the reconstruction of microbial metabolic pathways, revealing the genetic potential of the microbiome to produce specific neuroactive and hepatoactive compounds [13].

However, the presence of a gene does not guarantee its expression. Therefore, modern investigations heavily integrate metatranscriptomics, metaproteomics, and host multi-omics to construct a dynamic picture of the tripartite axis in real time. Metatranscriptomics measures the complete set of transcribed messenger RNA within the microbial community, reflecting which genes are actively being expressed under specific dietary or disease conditions. Concurrently, host transcriptomics applied to liver biopsies and specific brain regions isolated in preclinical models allows researchers to observe the precise host cellular response to microbial fluctuations. The integration of these vast datasets relies on advanced computational biology and machine learning algorithms, which can identify hidden correlations and predict causal relationships between specific microbial consortia and systemic metabolic phenotypes.

Table 1 Key Microbial Metabolites and Their Primary Physiological Targets in the Brain and Liver

Metabolite Class	Primary Microbial Source	Target Organ	Primary Physiological Action	Receptor or Pathway
Short-Chain Fatty Acids	Fermentative anaerobes	Liver	Inhibition of lipid synthesis	G-protein coupled receptors
Short-Chain Fatty Acids	Fermentative anaerobes	Brain	Modulation of microglial state	Histone deacetylase inhibition
Secondary Bile Acids	Clostridium species	Liver	Regulation of glucose output	Farnesoid X receptor
Lipopolysaccharides	Gram-negative bacteria	Liver	Induction of cytokine release	Toll-like receptor 4
Indole Derivatives	Tryptophan metabolizers	Brain	Alteration of astrocyte activity	Aryl hydrocarbon receptor

3.2 Tracking Metabolites from Gut to Brain and Liver

While sequencing technologies map the microbial potential, metabolomics provides the critical functional readout of the gut-brain-liver axis. The metabolome represents the complete set of small-molecule chemicals found within a biological sample, including those produced directly by microbes and those co-metabolized by the host. Researchers employ high-resolution analytical platforms, predominantly liquid chromatography coupled with tandem mass spectrometry and gas chromatography coupled with mass spectrometry, to identify and quantify thousands of metabolites in feces, portal blood, systemic plasma, and cerebrospinal fluid. By comparing the metabolomic profiles of portal and systemic blood, scientists can determine exactly which microbial metabolites are extracted by the liver and which evade hepatic clearance to enter systemic circulation and reach the brain [14].

Isotope tracing represents another critical methodological advancement in tracking these complex pathways. By feeding animal subjects dietary substrates labeled with stable isotopes, such as carbon-13 or deuterium, researchers can track the biochemical fate of a specific nutrient as it is processed by the gut microbiota, absorbed through the intestinal epithelium, sequestered by the liver, or transported across the blood-brain barrier. This technique unequivocally demonstrates the direct incorporation of microbially derived carbon skeletons into

neurotransmitters in the central nervous system and structural lipids in the liver, confirming the profound material contribution of the microbiome to host organ integrity.




Figure 1 Schematic of Gut

3.3 Pathological Scenarios and Disease Models

To establish definitive causality between microbiome alterations and systemic metabolic dysfunction, researchers rely extensively on highly controlled animal models. The gold standard for such investigations is the germ-free mouse model. These animals are born and raised in sterile isolators, completely devoid of any microbial exposure. Consequently, they exhibit profound physiological alterations, including altered hepatic lipid metabolism, compromised blood-brain barrier integrity, and atypical neurodevelopmental trajectories [15]. By introducing specific bacterial strains or defined consortia into these germ-free animals, researchers can pinpoint the exact metabolic and neurological consequences of individual microbes.

Furthermore, fecal microbiota transplantation serves as a powerful experimental tool. In these studies, the complex microbial community from a human patient suffering from metabolic disease is transplanted into a recipient germ-free mouse or a mouse whose endogenous microbiome has been depleted via broad-spectrum antibiotics. If the recipient animal subsequently develops features of the donor pathology, such as accelerated weight gain, hepatic steatosis, or neuroinflammation, it provides compelling evidence that the dysbiotic microbiome is not merely a consequence of the disease but an active driver of the pathology. Advanced integrative bioinformatics networks are then applied to these experimental models to cross-reference multi-organ transcriptomic changes with microbial population shifts, mapping complex regulatory networks that span multiple physiological systems [16]. These network models allow

researchers to simulate the potential outcomes of hypothetical interventions, drastically accelerating the pace of targeted therapeutic discovery [17].

4. Discussion of Therapeutic Opportunities

4.1 Microbial Interventions and Dietary Modulation

The realization that the gut microbiome serves as a central signaling hub has opened entirely new avenues for therapeutic intervention in metabolic disease. The most direct approach involves modulating the composition and function of the microbial community through targeted dietary interventions, prebiotics, and probiotics. Prebiotics, which are non-digestible food ingredients that beneficially affect the host by selectively stimulating the growth and activity of specific bacteria, represent a fundamental strategy for restoring metabolic homeostasis. By supplementing the diet with complex polysaccharides, clinicians can actively drive the expansion of beneficial, short-chain fatty acid-producing taxa. This targeted fermentation process not only lowers the luminal pH of the colon, creating a hostile environment for opportunistic pathogens, but also fortifies the mucosal barrier, thereby suppressing the initial trigger for systemic low-grade inflammation [18].

Probiotics, defined as live microorganisms that confer a health benefit when administered in adequate amounts, offer another layer of intervention. While traditional over-the-counter probiotic formulations have shown inconsistent efficacy in treating severe metabolic dysfunction, the next generation of precision probiotics holds immense clinical promise. Researchers are currently developing rationally designed consortia of highly characterized commensal bacteria specifically selected for their complementary metabolic functions. In parallel, clinical trials investigating the efficacy of rigorous, well-controlled fecal microbiota transplantation from metabolically healthy lean donors to obese patients with insulin resistance have demonstrated variable but intriguing improvements in peripheral insulin sensitivity and alterations in hepatic lipid partitioning [19]. Despite the regulatory and standardization challenges surrounding complex microbial transplants, these studies validate the immense therapeutic potential of entirely replacing a dysbiotic ecosystem.

4.2 Pharmacological Targeting of Metabolite Receptors

Beyond direct microbial manipulation, the pharmacological targeting of host receptors that interface with microbial metabolites represents a highly sophisticated strategy to hijack the communication pathways of the gut-brain-liver axis. The most prominent example of this in contemporary clinical practice is the development and widespread application of glucagon-like peptide-1 receptor agonists. These therapeutic agents, originally designed to mimic endogenous incretin hormones for the management of type 2 diabetes, have proven highly effective in inducing substantial weight loss and reversing hepatic steatosis. Interestingly, recent studies indicate that the profound metabolic benefits of these drugs are partially mediated by their complex interactions with the gut microbiome. The administration of these agonists alters gastrointestinal transit time, subsequently reshaping the microbial community architecture and

modifying the profile of luminal bile acids, which synergistically enhances the systemic metabolic outcome [20][21].

Similarly, the intricate signaling network of secondary bile acids has become a prime target for drug development. Pharmacological compounds designed to selectively agonize the farnesoid X receptor in the liver and intestine have shown significant efficacy in reducing hepatic lipid accumulation and attenuating liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis. By artificially stimulating this receptor, these drugs mimic the regulatory signals normally provided by a healthy, microbially modulated bile acid pool, thereby suppressing hepatic lipogenesis and reducing local inflammation [22]. Furthermore, the concept of psychobiotics represents an emerging frontier targeting the gut-brain axis specifically. By identifying microbial strains that produce neuroactive compounds capable of modulating vagal tone or suppressing central neuroinflammation, researchers aim to develop oral interventions that can ameliorate the psychological stress and aberrant feeding behaviors frequently associated with severe metabolic syndrome.

Table 2 Current and Emerging Therapeutic Interventions Targeting the Gut-Brain-Liver Axis

Intervention Type	**Specific Modality**	**Primary Axis Target**	**Expected Metabolic Outcome**
Microbial Modulation	Next-generation probiotics	Gut ecology	Restoration of mucosal barrier integrity
Dietary Intervention	Prebiotic fiber supplementation	Gut-Liver signaling	Increased short-chain fatty acid production
Pharmacological	Farnesoid X receptor agonists	Liver-Gut loop	Reduction of hepatic steatosis and fibrosis
Pharmacological	Glucagon-like peptide-1 agonists	Gut-Brain-Liver	Enhancement of satiety and insulin sensitivity
Ecosystem Transfer	Fecal microbiota transplantation	Systemic network	Global recalibration of host metabolism

5. Conclusion

5.1 Summary of Findings

The conceptualization of human metabolism as an isolated function of individual organs is fundamentally obsolete. The extensive body of evidence reviewed in this paper firmly establishes that metabolic homeostasis is governed by the intricate, continuous crosstalk between the gut microbiome, the brain, and the liver. The gut microbiota functions as a responsive bioreactor,

translating complex dietary inputs into a vast array of bioactive metabolites, including short-chain fatty acids and modified bile acids. These molecular messengers cross the intestinal barrier, traveling via the portal circulation to strictly regulate hepatic lipid and glucose metabolism, while simultaneously entering systemic circulation to influence neuroinflammation and central regulatory circuits. Concurrently, the vagus nerve and enteric nervous system provide a rapid neural communication highway, allowing the brain to monitor the luminal environment and coordinate systemic energy expenditure and feeding behaviors. The disruption of these communication pathways through diet-induced dysbiosis initiates a cascade of barrier dysfunction, systemic inflammation, and aberrant signaling that drives the progression of complex conditions such as obesity, type 2 diabetes, and severe hepatic steatosis.

5.2 Future Directions

As our understanding of this tripartite axis transitions from basic biological mapping to clinical translation, the future of metabolic disease management relies on the development of holistic, systems-level therapies. The integration of advanced multi-omics profiling and sophisticated machine learning algorithms will soon allow clinicians to map an individual patient's unique metabolic and microbial signature. This level of precision medicine will facilitate the deployment of customized interventions, ranging from rationally designed microbial consortia and targeted dietary regimens to highly specific pharmacological agents that modulate key metabolite receptors. Furthermore, emerging technologies such as precision microbiome editing via bacteriophages or clustered regularly interspaced short palindromic repeats hold the theoretical potential to surgically excise detrimental microbial pathways without disrupting the broader ecological balance [23]. Ultimately, mastering the language of the gut microbiome-brain-liver axis will empower the medical community to treat metabolic dysfunction at its systemic root, shifting the paradigm from symptom management to enduring metabolic restoration.

References

[1] Lu, Y., Shi, T., Liu, W., Shang, D., Liu, X., Wang, Q., ... & Duan, X. (2025). Supramonomer-Based Glyco-Cationic Nanoparticles With GSH Depletion-Enhanced Drug/Gene Co-Delivery for Combination Therapy. Medicine Bulletin, 1(2), 171-181.

[2] Guo, Hanzhong, et al. "Real-time one-step diffusion-based expressive portrait videos generation." arXiv preprint arXiv:2412.13479 (2024).

[3] Xu, X., Bowtell, J., Young, W. R., Fong, D. T., & Williams, G. K. (2026). Increased common corticospinal input during eyes-closed unilateral stance in people with chronic ankle instability. Scientific Reports.

[4] Xiao, Y., Xiao-yue, Z., Yue, W., Ruo-tao, L., Xiang-jie, L., Xing-yuan, W., ... & Zhen-yi, J. (2022). Use of computed tomography for the diagnosis of surgical sarcopenia: Review of recent research advances. Nutrition in Clinical Practice, 37(3), 583-593.

[5] Peng, Q., Zheng, C., & Chen, C. (2024). A dual-augmentor framework for domain generalization in 3d human pose estimation. In Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition (pp. 2240-2249).

[6] Xie, C., Zhu, D., Wang, Z., Zhang, H., & Wei, Z. (2026). Explainable AI for Mental Health Detection from Social Media: A Comparative Study of Traditional Machine Learning and a Large Language Model. Available at SSRN 6429778.

[7] Banerjee, S., Kwaan, M. R., Wu, Y., Ren, Y., & Xirasagar, S. (2023). Ostomy Surgery for Patients with Large Bowel Obstruction in the Modern Era: a Nationwide Inpatient Sample Study. Journal of Gastrointestinal Surgery, 27(3), 585-589.

[8] Chu, Y. B., Li, J., Jia, P., Cui, J., Zhang, R., Kang, X., ... & Zhang, S. (2021). Irf1-and Egr1-activated transcription plays a key role in macrophage polarization: A multiomics sequencing study with partial validation. International Immunopharmacology, 99, 108072.

[9] Wei, D., Lin, X., & Bresalier, R. S. (2025). Reframing cancer cachexia: the vagal brain–liver axis as a novel neuro-metabolic target. Signal Transduction and Targeted Therapy, 10(1), 370.

[10] Mi, L., Wang, W., Tu, W., He, Q., Kong, R., Fang, X., ... & Liu, Y. (2025, March). Empower vision applications with LoRA LMM. In Proceedings of the Twentieth European Conference on Computer Systems (pp. 261-277).

[11] Xu, X., Bowtell, J., Young, W. R., Fong, D. T., & Williams, G. K. (2025). Distinct patterns in neuromuscular adaptation to repeated perturbations in chronic ankle instability. Journal of NeuroEngineering and Rehabilitation.

[12] Cai, Lie, et al. "Deep learning model for breast shear wave elastography to improve breast cancer diagnosis (INSPiRED 006): An international, multicenter analysis." Journal of Clinical Oncology 43.32 (2025): 3482-3493.

[13] Song, S., Liu, Z., Wang, Y., & Gong, B. (2025). Human organoids and their application in tumor models, disease modeling, and tissue engineering. Medicine Bulletin, 1(1), 17-36.

[14] Kwaan, M. R., Ren, Y., Wu, Y., & Xirasagar, S. (2021). Colonic stent use by indication and patient outcomes: a nationwide inpatient sample study. Journal of Surgical Research, 265, 168-179.

[15] Gao, Z., Guo, M., Chen, K., Jiang, M. L., Zhang, L. M., Di Cesare Mannelli, L., & Zhang, C. J. (2025). Oligodendrocyte Precursor Cells in Demyelination Repair: Mechanisms, Crosstalk, and Therapeutic Frontiers. Medicine Bulletin, 1(2), 104-120.

[16] Yang, Y., Li, G., Zhong, Y., Xu, Q., Chen, B. J., Lin, Y. T., ... & Cai, J. J. (2023). Gene knockout inference with variational graph autoencoder learning single-cell gene regulatory networks. Nucleic acids research, 51(13), 6578-6592.

[17] Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., et al. (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences, 102(43), 15545–15550.

[18] Li, Y., Liao, X., Tang, S., Wang, Q., Lin, H., Yu, X., ... & Zhong, T. (2025). Potential Therapeutic Targets for Androgenetic Alopecia (AGA) in Obese Individuals as Revealed by a Gut Microbiome Analysis: A Mendelian Randomization Study. Nutrients, 17(11), 1892.

[19] Che, X., Wang, H., Wang, H., & Jiang, Y. Z. (2025). Intratumoral Nerve Phased Development: A Promising Therapeutic Target. Medicine Bulletin, 1(2), 154-170.

[20] Yang, D., Wang, X., Gao, Y., Liu, S., Ren, B., Yue, Y., & Yang, Y. (2025, October). Opengs-fusion: Open-vocabulary dense mapping with hybrid 3D Gaussian splatting for refined object-level understanding. In 2025 IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS) (pp. 21135-21142). IEEE.

[21] Yu, X., Zhang, Y., Yao, Y., Cho, W. C., & Shang, A. (2025). Biofilm-mediated immune dysregulation in chronic pulmonary diseases: mechanisms and clinical implications. Frontiers in Microbiology, 16, 1736384.

[22] Xie, C., Zhu, D., Wang, Z., Zhang, H., & Wei, Z. (2026). Compliance-Aware Discharge Agent for Auditable ICU Discharge Planning: A Pilot Feasibility Study Using Structured eICU Records. Available at SSRN 6429758.

[23] Tao, X., Chen, D., Liang, R., Zhang, X., Yu, X., Chung, S., ... & Xiao, Y. (2021). A comparative study on knowledge towards COVID-19 prevention among undergraduate students in Macao and Zhuhai, China. PeerJ, 9, e11833.